Deloitte China assists listing of HJ Science on SEHK
Deloitte China supported the listing of HJ Science Co., Ltd. - B ("HJ Science", stock code: 06132.HK) on the Stock Exchange of Hong Kong (SEHK) on 23 June 2026.
In this global offering, HJ Science offered 13.6 million shares at an offer price of HKD81.80 per share, raising approximately HKD1.11 billion.
Ryan Tan and Evan Zhu, Audit & Assurance (A&A) seniors of Deloitte China (first and second from the left); Dr. Ji Jianxin, founder, chairman, executive director and chief executive officer of HJ Science (seventh from the left); Ernest Lee, Deloitte China's Technical partner and a member of the Listing Committee of the SHEK (eighth from the left); Liu Yang, Western Region Offering Services leader of Deloitte China's Capital Market Services Group (CMSG) (ninth from the left); Dick Kay, National leader of CMSG (fifth from the right); Benjie Chan, Western Region Hong Kong Offering leader of CMSG (fourth from the right); Michael Yip, A&A partner (third from the right); Boto Li A&A manager (second from the right) and representatives of other intermediaries attend the listing ceremony of HJ Science.
(from left) Evan Zhu, Ryan Tan, Liu Yang, Dr. Ji Jianxin, Michael Yip and Boto Li attend the listing ceremony of HJ Science.
(from left) Evan Zhu, Benjie Chan, Ernst Lee, Michael Yip, Dick Kay, Liu Yang, Boto Li and Ryan Tan attend the listing ceremony of HJ Science.
Client overview
HJ Science is a clinical-stage biotech company founded by a team of industrial experts, dedicated to researching and developing therapies for autoimmune, metabolic and oncology diseases.
According to the company's prospectus, HJ Science has developed a strategically designed differentiated product pipeline comprising three core assets, namely HJ787, HJ178 and HJ891, all of which are self-developed small-molecule Category 1 innovative drugs as classified by the National Medical Products Administration of China.
According to CIC, HJ787 is the only topical selective tyrosine kinase 2 (TYK2) inhibitor in clinical development in China for both oral and topical treatments for atopic dermatitis (AD), neurodermatitis (ND) and psoriasis (Ps) and as topical treatment for acne vulgaris (AV).
Deloitte's role
The HJ Science listing spanned industry cycles, bearing witness to the resilience of the company's and Deloitte's teams. As a core service institution of this new listing engagement, Deloitte China has been deeply involved in the entire process from the company’s share reform to its IPO and fundraising. This successful listing demonstrates Deloitte's professional service capabilities in serving clients in capital markets. Our engagement team worked closely with various professional parties, provided high-quality services with rich industry experience and excellent professional capabilities to assist HJ Science in listing on the Main Board of the SEHK.
Deloitte China congratulates HJ Science on its successful listing on the SEHK. We will continue to provide high quality professional services and outstanding resources integration to assist more clients to take one-step ahead in today's increasingly competitive and complex business environment.
Deloitte refers to one or more of Deloitte Touche Tohmatsu Limited (“DTTL”), its global network of member firms, and their related entities (collectively, the “Deloitte organization”). DTTL (also referred to as “Deloitte Global”) and each of its member firms and related entities are legally separate and independent entities, which cannot obligate or bind each other in respect of third parties. DTTL and each DTTL member firm and related entity is liable only for its own acts and omissions, and not those of each other. DTTL does not provide services to clients. Please see About Deloitte to learn more.
Deloitte China provides integrated professional services, with our long-term commitment to be a leading contributor to China’s reform, opening-up and economic development. We are a globally connected firm with deep roots locally, owned by our partners in China. With over 20,000 professionals across 31 Chinese cities, we provide our clients with a one-stop shop offering world-leading audit, tax and consulting services.
We serve with integrity, uphold quality and strive to innovate. With our professional excellence, insight across industries, and intelligent technology solutions, we help clients and partners from many sectors seize opportunities, tackle challenges and attain world-class, high-quality development goals.
The Deloitte brand originated in 1845, and its name in Chinese (德勤) denotes integrity, diligence and excellence. Deloitte's global professional network of member firms now spans more than 150 countries and territories. Through our mission to make an impact that matters, we help reinforce public trust in capital markets, enable clients to transform and thrive, empower talents to be future-ready, and lead the way toward a stronger economy, a more equitable society and a sustainable world.
This communication contains general information only, and none of Deloitte Touche Tohmatsu Limited (“DTTL”), its global network of member firms or their related entities (collectively, the “Deloitte organization”) is, by means of this communication, rendering professional advice or services. Before making any decision or taking any action that may affect your finances or your business, you should consult a qualified professional adviser.
No representations, warranties or undertakings (express or implied) are given as to the accuracy or completeness of the information in this communication, and none of DTTL, its member firms, related entities, employees or agents shall be liable or responsible for any loss or damage whatsoever arising directly or indirectly in connection with any person relying on this communication. DTTL and each of its member firms, and their related entities, are legally separate and independent entities.
